Share this article
Go deeper with GlobalData
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Perrigo completed the sale of Tysabri drug royalty to RPI for $2.85bn, London's Institute of Cancer Research (ICR) revealed new secrets about the genetic causes of cancer, and Eli Lilly acquired CoLucid Pharmaceuticals for $960m. Pharmaceutical-technology.com wraps up the key headlines from March.
April 2, 2017